Introduction
There is compelling evidence that impaired functioning of the glutamatergic N-methyl-D-aspartate receptor (NMDAR) can produce psychotic symptoms and is implicated in the pathogenesis of some cases of schizophrenia (Javitt and Zukin, 1991; Dalmau et al., 2011; Steiner et al., 2013 ; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014; Genovese et al., 2016; Curtis et al., 2018; Tsavou and Curtis, 2019) . The functioning of NMDAR can be enhanced by blockers of glycine transporter 1 (GlyT-1), which produce increased activation of the modulatory site at which glycine acts as a co-agonist (Hashimoto, 2014) . GlyT-1 blockers have been trialled as treatments for schizophrenia. In a trial of bitopertine monotherapy compared against olanzapine or placebo in patients with an exacerbation of schizophrenia, all groups improved to a similar extent (BugarskiKirola et al., 2014) . Sarcosine, another GlyT-1 blocker, was superior to placebo in a number of studies (Tsai et al., 2004; Lane et al., 2005 Lane et al., , 2010 Strzelecki, Urban-Kowalczyk and Wysokiński, 2018) but in others no difference was demonstrated (Lane et al., 2006 (Lane et al., , 2008 .
If blocking GlyT-1 has a therapeutic effect in schizophrenia then it would be reasonable to expect that genetic variants damaging SLC6A9, the gene which codes for it, might be protective against schizophrenia. Homozygous variants in SLC6A9 can cause severe encephalopathy (Alfadhel et al., 2016; Kurolap et al., 2016) but no phenotypic effects have been described from heterozygous variants except for one report that rs16831558, which lies 2.1 kb upstream, may impact response to clozapine treatment (Taylor et al., 2016) .
The hypothesis that damaging variants of SLC6A9 might be protective against schizophrenia was examined using data from a study of exome-sequenced cases and controls.
Methods
The Swedish schizophrenia study, which had initially been tested for an excess of ultra-rare variants, was subsequently subjected to a weighted burden analysis, as reported previously (Genovese et al., 2016; Curtis et al., 2018) . Whole exome sequence data was downloaded from dbGaP and, as explained previously, subjects with a substantial Finnish ancestry component were removed leaving a sample of 4225 cases and 5834 controls. Variants were annotated using VEP, PolyPhen and SIFT (Kumar, Henikoff and Ng, 2009; Adzhubei, Jordan and Sunyaev, 2013; McLaren et al., 2016) . After applying appropriate quality control measures, a weighted burden analysis of SLC6A9 was performed using GENEVARASSOC and SCOREASSOC similar to the previous analysis, except that attention was not restricted to only rare variants (Curtis, 2012 (Curtis, , 2016 . GENEVARASSOC assigns functional weights to each variant based on the predicted effect on the functions of the gene so that, for example, a nonsynonymous variant is given a weight of 10 and a stop gained mutation a weight of 20. To these weights were added 10 if the variant was predicted to be deleterious by SIFT and 10 if it was predicted to be possibly or probably damaging by PolyPhen. SCOREASSOC then multiplies this functional weight by a frequency weighting factor so that very rare variants are weighted 10 times higher than common ones of the same type. The reasoning for including common variants in the analysis was that there might not be strong selection pressure against protective variants and hence they might not be particularly rare.
Results
On examining the results of the weighted burden test, it was apparent that more of the variants with the highest weights were seen among controls rather than cases. There were no variants predicted to completely disrupt gene functioning, i.e. stop mutations or essential splice site variants, and so the variants with the highest weights were those nonsynonymous variants which were identified as both deleterious by SIFT and also as damaging by Polyphen. These variants are listed in Table 1 along with their genotype counts. VEP annotation was performed for each transcript of SLC6A9 and the weights were assigned based on the most damaging annotation for any transcript. Table 1 provides an example of one of the transcripts with such an annotation.
Although if one counts the listed variants then more occur in controls than cases, it can be seen that 1:44466494-G/A is commoner than the others and occurs in 18 controls and 17 cases, one of which is homozygous for the alternate allele. Thus if this variant is included then the count of subjects possessing a variant allele does not differ much between controls and cases. However there are two reasons to question the validity of the genotypes for this variant. The first is that there is a subject who is called as a homozygote but one would only expect 3 subjects per million to be homozygous given that the observed frequency of the alternate allele is 0.0018. The second reason to be suspicious is that according to gnomAD the frequency for this allele among non-Finnish Europeans, based on 64084 subjects, is only 0.00039 and is even lower in other populations (Lek et al., 2016) . This is quite incompatible with the results we observe. Examination of the calls for this variant as provided in the VCF file does not reveal any obvious problems. All the calls are based on a large number of reads, with the minimum depth being 35 and roughly similar numbers of reads for each allele in the heterozygotes. The homozygote has 48 reads for the alternate allele and none for the reference. Nevertheless, given that the frequency is incompatible with ExAC and given that the observation of a homozygote would be extremely unlikely even with the observed frequency it seems at least plausible that the calls for this variant are simply wrong for some unknown reason.
If 1:44466494-G/A is ignored then variants predicted to severely affect functioning of SLC6A9 are observed 15 times in controls and 5 times in cases, with the ratio of controls to cases being 5834/4225=1.4. Given that this is a post hoc observation it is not appropriate to provide a formal p value.
Discussion
The results are consistent with the hypothesis that genetic variants severely affecting functioning of SLC6A9 are protective against schizophrenia if one either assumes that the genotypes at 1:44466494-G/A are mistaken or that this variant does not actually have a severe effect in spite of the predictions of SIFT and PolyPhen. Predicting the effects of coding variants on gene functioning is an imprecise art and if one wanted more certainty about the impact of these variants one would need to study them in a model system such as cultured cells. The present small study is obviously not conclusive but can serve to generate predictions which can be tested as larger samples become available. If further evidence accrues that damage to SLC6A9 is protective against schizophrenia then this might provide additional motivation to develop pharmacological interventions which target GlyT-1 or which seek to boost NMDAR functioning in other ways.
Table 1
Genotype counts for variants in SLC6A9 which are predicted both as deleterious by SIFT and as damaging by PolyPhen. For each variant an example transcript is shown which has both these annotations. 
